Peritonitis and Other Complications

  • Charles E. Halstenson
  • William F. Keane

Abstract

Infection is the most frequent clinical complication in patients with end-stage renal disease maintained on peritoneal dialysis (1). These infections include bacterial and fungal peritonitis as well as exit-site and catheter tunnel infections. The incidence of peritonitis is 3 to 5 times higher in patients maintained on continuous ambulatory peritoneal dialysis (CAPD) than in those on intermittent peritoneal dialysis and contributes to the morbidity and mortality of patients receiving CAPD therapy (2). During the 1980s the incidence of peritonitis was about 1.3 episodes per patient per year (3). This rate has declined over time with the introduction of various types of disconnect systems (4). These disconnect systems have predominantly decreased the risk of peritonitis due to skin organisms, e.g., coagulase-negative staphylococcus. The Y set, an example of disconnect technology, has also been associated with a decrease in the peritonitis rate to 1 episode per 24–36 months (5,6).

Keywords

Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Peritoneal Dialysis Patient Chronic Peritoneal Dialysis Peritonitis Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nolph Kd, Cutler SJ, Steinberg SM, Novak JW, Hirschman GH: Factors associated with morbidity and mortality among patients on CAPD. ASAIO Trans 33: 57–65, 1987.CrossRefGoogle Scholar
  2. Excerpts from United States Renal Data System 1993 Annual Data Report. Am J Kidney Dis 22: 53–57, 1993.Google Scholar
  3. Nolph KD, Lindblad AS, Novak JW: Current concepts. Continuous ambulatory peritoneal dialysia. Clinical Coordinating Center, National Institutes of Health Continuous Ambulatory Peritoneal Dialysis Registry. N Engl J Med 318: 1595–1600, 1988.CrossRefGoogle Scholar
  4. Bernardini J, Holley JL, Johnston JR, Paerlmutter JA, Piraino B: An analysis of ten-year trends in infections in adults on continuous ambulatory peritoneal dialysis (CAPD). Clin NAephrol 36: 29–34, 1991.Google Scholar
  5. Fellin G, Gentile MG, Manna GM: Peritonisis prevention: Y connector and sodium hypochioite. Three years experience. Report of the Italian Study Group. In: R Khanna, KD Nolph, B Prowant, ZJ Twardowski, DG Oreopoulis, eds, Advances in Peritoneal Dialysis. Peritoneal Dialysis International, Toronto, pp 114–118, 1987.Google Scholar
  6. Churchill DN, Taylor DW, Vas SI, Oreopoulos DG, Bettcher KB, Fenton SSA, Fine A, Lavoie S, Page D, Wu G, Beecroft ML, Pemberton R, Wilczynski NL, de Veber GA, Williams W: Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): a multicenter randomized cliical trial comparing the Y-connectou disinfectant system to standard systems. Perit Dial Int 9: 159–163, 1989.Google Scholar
  7. Michael J, Adu D, Frier LD, Mcintyre M: Bacteriological spectrum of CAPD peritonitis. Contrib Nephrol 57:41–44, 1987.Google Scholar
  8. 8.
    Golper TA, Hartstein AI: Analysis of the causative pathogens in uncomplicated CAPD-associated peritonitis: duration of therapy, relapses, and prognosis. Am J Kidney Dis 7: 141–145, 1986.PubMedGoogle Scholar
  9. 9.
    Rubin J, Kirschner K, Walsh D, et al.: Fungal peritonitis during continuous ambulatory peritoneal dialysis: a report of 17 cases. Am J Kidney Dis 10: 361–368, 1987.PubMedGoogle Scholar
  10. 10.
    Scalamogna A, Castelnovo C, De Vecchi A, Ponticelli C: Exit-site and tunnel infections in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 18: 674–677, 1991.PubMedGoogle Scholar
  11. 11.
    Mion C, Slingeneyer A, Canaud B: Peritonitis. In: R Gokal, ed, Continuous Ambulatory Peritoneal Dialysis,. Churchill Livingstone, New York, pp 163–217, 1986.Google Scholar
  12. 12.
    Marrie TJ, Noble MA, Costerton JW: Examination of the morphology of bacteria adhering to peritoneal dialysis catheters by scanning and transmission electron microscopy. J Clin Microbiol 18:1388–1398, 1983.Google Scholar
  13. 13.
    Dasgupta MK, Bettcher KB, Ulan RA, Burns V, Lam K, Dossetor JB, Costerton JW: Relationship of adherent bacterial biofilms to peritonitis in chronic ambulatory peritoneal dialysis. Petit Dial Bull 7: 168–173, 1987.Google Scholar
  14. 14.
    Harrison M, Keane WF: Host defense mechanisms in CAPDassociated peritonitis. Semin Dial 2: 117–121, 1989.CrossRefGoogle Scholar
  15. 15.
    Cotran RS, Karnovsky MJ: Ultrastructural studies on the permeability of the mesothelium to horseradish peroxidase. J Cell Biol 37: 123–137, 1968.PubMedCrossRefGoogle Scholar
  16. 16.
    Casley-Smith JR: An electron microscopical study of the passage of ions through the endothelium of lymphatic and blood capillaries, and through the mesothelium. Q J Exp Physiol Cogn Med Sci 52: 105–113, 1967.PubMedGoogle Scholar
  17. 17.
    Gilmour J, Tymiansky R, Pierratos A, Vas S, Klein M, Khanna R, Digenis D, Cuff S, Oreopoulos DG: Changes in some inflammatory proteins during peritonitis in CAPD patients. Petit Dial Bull 3: 201–204, 1983.Google Scholar
  18. 18.
    Rubin J, Lin LM, Lewis R, Cruse J, Bower JD: Host defense mechanisms in continuous ambulatory peritoneal dialysis. Clin Nephrol 20: 140–144, 1983.PubMedGoogle Scholar
  19. 19.
    Verbrugh HA, Keane WA, Hoidal JR, Freiberg MR, Elliot GR, Peterson PK: Peritoneal macrophages and opsonins: antibacterial defense in patients on chronic peritoneal dialysis. J Infect Dis 147: 1018–1029, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    Clark LA, Easmon CS: Opsonic activity of intravenous immunoglobulin preparations against Staphylococcus epidermidis. J Clin Pathol 39: 856–860, 1986.PubMedCrossRefGoogle Scholar
  21. 21.
    Lamperi S, Carozzi S: Defective opsonic activity of peritoneal effluent during continuous ambulatory peritoneal dialysis (CAPD): importance and prevention. Petit Dial Bull 6: 87–92, 1986.Google Scholar
  22. 22.
    Lamperi S, Carozzi S: Suppressor resident peritoneal macrophages and peritonitis incidence in continuous ambulatory peritoneal dialysis. Nephron 44: 219–225, 1986.PubMedCrossRefGoogle Scholar
  23. 23.
    Peterson PK, Gaziano E, Devalon M, Peterson LA, Keane WF: Antimicrobial activities of dialysate elicited and resident human peritoneal macrophages. Infect Immunol 49: 212–218, 1985.Google Scholar
  24. 24.
    Wierusz-Wysocka B, Wysocki H, Michta G, Wykretowicz A, Czarnecki R, Baczyk K: Phagocytosis and neutrophil bactericidal capacity in patients with uremia. Folia Haematol 111: 589–594, 1984.Google Scholar
  25. 25.
    Huttunen K, Lampainen E, Silvennoinen-Kassinen S, Tiilikainen A: The neutrophil function of uremic patients treated by hemodialysis or CAPD. Scand J Urol Nephrol 18: 167–172, 1984.PubMedCrossRefGoogle Scholar
  26. 26.
    Duwea K, Vas SI, Weatherhead JW: The effect of the composition of peritoneal dialysis fluid on chemiluminescence phagocytosis and bactericidal activity in vitro. Infect Immunol 33: 130–135, 1981.Google Scholar
  27. 27.
    Harvey DM, Sheppard KJ, Morgan AG, Fletcher J: Effect of dialysate fluids on phagocytosis and killing by normal neutrophils. J Clin Microbiol 25: 1424–1427, 1987.PubMedGoogle Scholar
  28. 28.
    McGregor SJ, Brock JH, Briggs JD, Junor BJ: Bactericidal activity of peritoneal macrophages from continuous ambulatory dialysis patients. Nephrol Dial Transplant 2: 104–108, 1987.PubMedGoogle Scholar
  29. 29.
    Alobaidi HM, Coles GA, Davies M, Lloyd D: Host defense in continuous ambulatory peritoneal dialysis: the effect of dialysate on phagocyte function. Nephrol Dial Transplant 1: 16–21, 1986.PubMedGoogle Scholar
  30. 30.
    Millikin SP, Matzke GR, Keane WF: Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Petit Dial Int 11: 252–260, 1991.Google Scholar
  31. 31.
    Keane WF, Everett ED, Golper TA, Gokal R, Halstenson C, Kawaguchi Y, Riella M, Vas S, Verbrugh HA: Peritoneal dialysis-related peritonitis treatment recommendations. 1993 update. The Ad Hoc Advisory Committee on Peritonitis Management. International Society for Peritoneal Dialysis. Petit Dial Int 13: 14–28, 1993.Google Scholar
  32. 32.
    Gilbert DN: Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35: 399–405, 1991.PubMedCrossRefGoogle Scholar
  33. 33.
    Haqqie SS, Bailie GR, Eisele G: Once-daily gentamicin and once-weekly vancomycin intraperitoneally to treat CAPD peritonitis (abstract). Petit Dial Int 14: S79, 1994.Google Scholar
  34. 34.
    Weaver ME, Dunbeck DC: Mupirocin (Bactroban) causes permanent structural changes in peritoneal dialysis catheters (abstract). Petit Dial Int 14: S20, 1994.Google Scholar
  35. 35.
    Piraino B, Barnardini J, Lutes R, Johnston J, Holley J: Randomized trial of mupirocin at exit site vs oral rifampin to prevent S. Aureus catheter infections (abstract). Petit Dial Int 14: S27Google Scholar
  36. 36.
    Poole-Warren LA, Hallett MD, Hone PW, Burden SH, Farrell PC: Vaccination for the prevention of CAPDassociated staphylococcal infection: results of a prospective multicentre clinical trial. Clin Nephrol 35: 198–206, 1991.PubMedGoogle Scholar
  37. 37.
    Keane WP: Peritoneal Dialysis International 16: 557–573, 1996.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Charles E. Halstenson
    • 1
  • William F. Keane
    • 2
  1. 1.The Drug Evaluation Unit, Hennepin County Medical CenterUniversity of Minnesota College of PharmacyMinneapolisUSA
  2. 2.The Drug Evaluation Unit, Department of Medicine, Hennepin County Medical CenterUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations